Daptomycin-Induced Pulmonary Toxicity: A Case Series

Area of Science:

• Pharmacology
• Pulmonology
• Infectious Diseases

Background:

• Daptomycin is a critical antibiotic for treating infections caused by resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE).
• Adverse effects of daptomycin, while generally manageable, require ongoing surveillance and characterization.
• Eosinophilic pneumonia (EP) is an uncommon pulmonary complication associated with certain medications.

Observation:

• This report details two cases of patients who developed eosinophilic pneumonia.
• Both patients were undergoing treatment with daptomycin for their respective infections.
• The onset of respiratory symptoms occurred during or shortly after daptomycin therapy.

Findings:

• The clinical presentation in both patients was consistent with drug-induced eosinophilic pneumonia.
• Cessation of daptomycin therapy led to improvement in respiratory symptoms.
• Histopathological findings, where available, supported the diagnosis of eosinophilic pneumonia.

Implications:

• This case series highlights the importance of considering eosinophilic pneumonia in patients treated with daptomycin, especially those presenting with unexplained pulmonary symptoms.
• Early recognition and discontinuation of daptomycin may be crucial for favorable outcomes in drug-induced EP.
• Further research into the mechanisms and incidence of daptomycin-associated eosinophilic pneumonia is warranted to refine clinical guidelines and patient monitoring.